BioCentury
ARTICLE | Clinical News

Dulaglutide: Phase II data

May 28, 2012 7:00 AM UTC

Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Dulaglutide ( GLP-1Fc) ( LY2189265) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 (GLP-1) Description: Long-acting...